Wang Bing, Wang Shan, Liang Guowei, Xu Jianjun, Zhou Rouli, Zhang Qingyun
1 Department of Clinical Laboratory, Aerospace Central Hospital, Beijing, China.
2 Department of Clinical Laboratory, Civil Aviation General Hospital, Beijing, China.
Tumour Biol. 2017 Jun;39(6):1010428317705518. doi: 10.1177/1010428317705518.
Pancreatic carcinoma is an aggressive malignancy with particularly low 5-year survival rate. In order to improve the dismal survival rate, identification of new potential susceptibility risk factors for the prevention and early detection of pancreatic carcinoma is of utmost importance. Lysosomal protein transmembrane 4 beta has two alleles designated as LAPTM4B1 and LAPTM4B2. The aim of this study was to investigate the association between lysosomal protein transmembrane 4 beta gene polymorphism and the risk of pancreatic carcinoma in China. A population-based case-control analysis was performed in 233 patients with pancreatic carcinoma and 842 control subjects. The genotypes of lysosomal protein transmembrane 4 beta were determined by utilizing polymerase chain reaction based on specific primers. The χ test was used to analyze the differences of categorical variables and Hardy-Weinberg equilibrium. Odds ratio and 95% confidence intervals were computed using an unconditional logistic regression model. A significant difference in the frequency of LAPTM4B2 was observed between the patients and the controls (33.05% vs 27.55%, p = 0.03). LAPTM4B2 had a 1.33-fold (95% confidence interval: 1.04-1.71) higher risk for developing pancreatic carcinoma when compared with LAPTM4B1 carriers. We found that the frequency of LAPTM4B1/2 + 2/2 in pancreatic carcinoma group was higher than that in the control group (57.94% vs 48.34%, p = 0.01). However, no significant association was observed between lysosomal protein transmembrane 4 beta genotypes and gender, age, family history of cancer, smoking/alcohol status, histopathological differentiation, lymph node metastasis, clinical stage, or serum cancer antigen 19-9 level. These findings indicate that the LAPTM4B2 allele is associated with the high risk of pancreatic carcinoma and carrying LAPTM4B*2 may be a susceptible factor to Chinese pancreatic carcinoma patients.
胰腺癌是一种侵袭性恶性肿瘤，5年生存率极低。为了提高这一令人沮丧的生存率，识别新的潜在易感性风险因素对于胰腺癌的预防和早期检测至关重要。溶酶体蛋白跨膜4β有两个等位基因，分别命名为LAPTM4B1和LAPTM4B2。本研究的目的是探讨溶酶体蛋白跨膜4β基因多态性与中国胰腺癌发病风险之间的关联。对233例胰腺癌患者和842例对照者进行了基于人群的病例对照分析。利用基于特异性引物的聚合酶链反应测定溶酶体蛋白跨膜4β的基因型。采用χ检验分析分类变量的差异和Hardy-Weinberg平衡。使用无条件逻辑回归模型计算比值比和95%置信区间。患者和对照者之间LAPTM4B2的频率存在显著差异（33.05%对27.55%，p = 0.03）。与LAPTM4B1携带者相比，LAPTM4B2患胰腺癌的风险高1.33倍（95%置信区间：1.04-1.71）。我们发现胰腺癌组中LAPTM4B1/2 + 2/2的频率高于对照组（57.94%对48.34%，p = 0.01）。然而，未观察到溶酶体蛋白跨膜4β基因型与性别、年龄、癌症家族史、吸烟/饮酒状况、组织病理学分化、淋巴结转移、临床分期或血清癌抗原19-9水平之间存在显著关联。这些发现表明，LAPTM4B2等位基因与胰腺癌的高风险相关，携带LAPTM4B*2可能是中国胰腺癌患者的一个易感因素。
